SCHEMBL7201722

SCHEMBL7201722

COc1ccc2c(c1)OC(C(=O)O)=CO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
MTNR1A P48039 1/20 0.41
ALDH1A1 P00352 4/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA12 O43570 3/20 0.41
CA9 Q16790 3/20 0.41
CA3 P07451 2/20 0.41
HPGD P15428 2/20 0.41
CA5A P35218 2/20 0.41
CA7 P43166 2/20 0.41
CA14 Q9ULX7 2/20 0.41
CA5B Q9Y2D0 2/20 0.41
CA6 P23280 1/20 0.41
PTGS2 P35354 4/20 0.40
PTGS1 P23219 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
AKR1C3 P42330 3/20 0.39
AKR1C2 P52895 3/20 0.39
CDC42 P60953 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7819674 0.95 KDM4E (0.44) KDM4EMTNR1AALDH1A1CA1CA2
SCHEMBL7203116 0.86 SMN1; SMN2 (0.43) KDM4EMTNR1AALDH1A1CA1CA2
SCHEMBL9255645 0.83 CA12 (0.47) KDM4EMTNR1AALDH1A1CA1CA2
SCHEMBL7818300 0.81 KDM4E (0.47) KDM4EALDH1A1CA2CA12CA9
SCHEMBL8113907 0.78 AKR1C2 (0.47) KDM4EMTNR1AALDH1A1HPGDPTGS1
SCHEMBL8580296 0.78 MAOB (0.49) KDM4EMTNR1AALDH1A1CA2CA12
SCHEMBL5337947 0.77 POLB (0.44) KDM4EALDH1A1CA12HPGDSMN1; SMN2
SCHEMBL7817781 0.73 CA12 (0.37) ALDH1A1CA1CA2CA12CA9
SCHEMBL7819754 0.73 KDM4E (0.44) KDM4EALDH1A1HPGDSMN1; SMN2AKR1C3
SCHEMBL4204148 0.72 MTNR1A (0.42) MTNR1AALDH1A1CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 KDM4E 2431/4885MTNR1A 1/4885ALDH1A1 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.